Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
Incyte (INCY) Stock Price & Analysis
1,589 Followers
INCY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$50.27 - $67.37
Previous Close$65.87
Volume1.56M
Average Volume (3M)3.61M
Market Cap
$14.81B
Enterprise Value$11.19B
Total Cash (Recent Filing)$3.66B
Total Debt (Recent Filing)$32.60M
Price to Earnings (P/E)20.0
Beta0.61
Next Earnings
Jul 30, 2024EPS Estimate
$0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding224,540,751
10 Day Avg. Volume6,958,387
30 Day Avg. Volume3,608,226
Standard Deviation0.09
R-Squared0.21
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.89
Price to Sales (P/S)3.84
Price to Cash Flow (P/CF)24.00
P/FCF Ratio24.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit3.25
Enterprise Value/Ebitda11.33
Forecast
1Y Price Target
$69.33Price Target Upside5.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Incyte News
Bulls Say, Bears Say
Bulls Say
AcquisitionThe acquisition has the potential to offer patients once-daily oral treatments for inflammatory indications, highlighting Incyte’s growing focus on the multi-billion dollar inflammation and autoimmune (IAI) space.
Clinical Trial SuccessEP262 demonstrated an excellent safety profile in a Phase 1 trial, with no serious adverse events or discontinuations, and a lower adverse event rate compared to placebo.
Share BuybackThe tender offer was fully subscribed, leading to a $2B share buyback at $60/share, representing 15% of outstanding shares.
Bears Say
Pipeline FailuresPipeline failures give pause on life after Jakafi; recent wins such as povorcitinib and axatilimab may not be enough to offset a major loss of exclusivity.
Revenue GrowthJakafi revenue growth continues to slow, and high Medicare utilization makes Incyte unattractive to a buyer.
Share Buyback$2B share buy back appears to do little to increase shareholder value, while making it more difficult to acquire and expand the pipeline.
---
Ownership Overview
37.10% Insiders
22.11% Mutual Funds
23.51% Other Institutional Investors
17.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $50.27 and its highest was $67.36 in the past 12 months.
What is Incyte Corp’s market cap?
Currently, no data Available
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Jul 30, 2024 which is in 8 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Apr 30, 2024. The company reported $0.643 earnings per share for the quarter, missing the consensus estimate of $0.798 by -$0.155.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is $0.93.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 224,854,550 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $0.643 in its last earnings report, missing expectations of $0.798. Following the earnings report the stock price went down -0.97%.
Which hedge fund is a major shareholder of Incyte Corp?
Among the largest hedge funds holding Incyte Corp’s share is Baker Bros Advisors LP. It holds Incyte Corp’s shares valued at 2B.
---
Incyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$69.33 (5.25% Upside)
$69.33 (5.25% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 91%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 783.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.72%
12-Months-Change
Fundamentals
Return on Equity
15.13%
Trailing 12-Months
Asset Growth
23.08%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
---
INCY Company Deck
---
INCY Earnings Call
Q1 2024
0:00 / 0:00
---
INCY Revenue Breakdown
85.65% Product revenues, net
14.16% Product royalty revenues
0.19% Milestone and contract revenues
---
INCY Stock 12 Month Forecast
Average Price Target
$69.33
▲(5.25% Upside)
Technical Analysis
Best Analysts Covering INCY
1 Year
1 Year Success Rate
16/19 ratings generated profit
1 Year Average Return
+8.73%
reiterated a buy rating 2 months ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +8.73% per trade.
---